111 (NASDAQ:YI) Receives “Sell (D-)” Rating from Weiss Ratings

Weiss Ratings reissued their sell (d-) rating on shares of 111 (NASDAQ:YI) in a report issued on Saturday,Weiss Ratings reports.

111 Stock Performance

NASDAQ:YI opened at $10.21 on Friday. The company has a market capitalization of $87.32 million, a P/E ratio of -2.55 and a beta of 0.46. The stock’s 50 day moving average price is $7.34 and its 200 day moving average price is $7.35. 111 has a 52 week low of $4.15 and a 52 week high of $14.10.

111 (NASDAQ:YI) last announced its quarterly earnings results on Thursday, March 20th. The company reported ($0.04) EPS for the quarter. The firm had revenue of $527.14 million for the quarter.

Institutional Investors Weigh In On 111

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. grew its holdings in 111 by 43,619.9% during the fourth quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company’s stock valued at $191,000 after purchasing an additional 305,339 shares during the last quarter. Napean Trading & Investment Co Singapore PTE Ltd acquired a new stake in shares of 111 in the fourth quarter worth $245,000. Finally, FIL Ltd bought a new stake in shares of 111 during the 4th quarter worth $450,000. 21.32% of the stock is currently owned by institutional investors and hedge funds.

About 111

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.